Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

HDL lowers the risk for atherosclerotic cardiovascular disease by promoting cholesterol efflux from macrophage foam cells. However, other antiatherosclerotic properties of HDL are poorly understood. To test the hypothesis that the lipoprotein carries proteins that might have novel cardioprotective activities, we used shotgun proteomics to investigate the composition of HDL isolated from healthy subjects and subjects with coronary artery disease (CAD). Unexpectedly, our analytical strategy identified multiple complement-regulatory proteins and a diverse array of distinct serpins with serine-type endopeptidase inhibitor activity. Many acute-phase response proteins were also detected, supporting the proposal that HDL is of central importance in inflammation. Mass spectrometry and biochemical analyses demonstrated that HDL3 from subjects with CAD was selectively enriched in apoE, raising the possibility that HDL carries a unique cargo of proteins in humans with clinically significant cardiovascular disease. Collectively, our observations suggest that HDL plays previously unsuspected roles in regulating the complement system and protecting tissue from proteolysis and that the protein cargo of HDL contributes to its antiinflammatory and antiatherogenic properties.

[1]  I. Young,et al.  High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation Published, JLR Papers in Press, October 25, 2006. , 2007, Journal of Lipid Research.

[2]  Rebekah L. Gundry,et al.  Investigation of an albumin‐enriched fraction of human serum and its albuminome , 2007, Proteomics. Clinical applications.

[3]  D. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.

[4]  J. Heinecke,et al.  Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. , 2006, Current opinion in cardiology.

[5]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.

[6]  A. Tall,et al.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.

[7]  R. Mahley,et al.  Putting cholesterol in its place: apoE and reverse cholesterol transport. , 2006, The Journal of clinical investigation.

[8]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[9]  G. Hortin,et al.  Diverse range of small peptides associated with high-density lipoprotein. , 2006, Biochemical and biophysical research communications.

[10]  Farhad Rezaee,et al.  Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.

[11]  A. Lucas,et al.  Serpins, the vasculature, and viral therapeutics. , 2006, Frontiers in bioscience : a journal and virtual library.

[12]  K. Resing,et al.  Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.

[13]  S. Hajduk,et al.  Human High Density Lipoproteins Are Platforms for the Assembly of Multi-component Innate Immune Complexes* , 2005, Journal of Biological Chemistry.

[14]  Eugene A. Kapp,et al.  Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.

[15]  M. Heller,et al.  Mass spectrometry‐based analytical tools for the molecular protein characterization of human plasma lipoproteins , 2005, Proteomics.

[16]  J. Kaye,et al.  Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro , 2005, Journal of neuroscience research.

[17]  Per Leanderson,et al.  Lipoproteomics II: Mapping of proteins in high‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry , 2005, Proteomics.

[18]  Chang Yeop Han,et al.  Thematic review series : The Immune System and Atherogenesis Lipoprotein-associated inflammatory proteins : markers or mediators of cardiovascular disease ? , 2005 .

[19]  D. Hoyert,et al.  Deaths: preliminary data for 2003. , 2005, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[20]  K. Resing,et al.  Proteomics strategies for protein identification , 2005, FEBS letters.

[21]  A. Boodhoo,et al.  The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. , 2005, Clinical chemistry.

[22]  Donna L. Hoyert,et al.  Deaths: preliminary data for 2003 (USA) , 2005 .

[23]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[24]  A. Chait,et al.  Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.

[25]  R. Aebersold,et al.  A Dataset of Human Liver Proteins Identified by Protein Profiling Via Isotope-coded Affinity Tag (ICAT) and Tandem Mass Spectrometry*S , 2004, Molecular & Cellular Proteomics.

[26]  V. Hascall,et al.  Inter-α-trypsin Inhibitor, a Covalent Protein-Glycosaminoglycan-Protein Complex* , 2004, Journal of Biological Chemistry.

[27]  A. Chait,et al.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Michael Kinter,et al.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.

[29]  V. Schumaker,et al.  Virtual two‐dimensional gel electrophoresis of high‐density lipoproteins , 2004, Electrophoresis.

[30]  E. Birney,et al.  The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.

[31]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[32]  G. Getz,et al.  Paraoxonase, a cardioprotective enzyme: continuing issues , 2004, Current opinion in lipidology.

[33]  Aldons J Lusis,et al.  Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.

[34]  V. Hascall,et al.  Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. , 2004, The Journal of biological chemistry.

[35]  Bing Zhang,et al.  GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies , 2004, BMC Bioinformatics.

[36]  Gil Atzmon,et al.  Unique lipoprotein phenotype and genotype associated with exceptional longevity. , 2003, JAMA.

[37]  John R Yates,et al.  Reproducibility of quantitative proteomic analyses of complex biological mixtures by multidimensional protein identification technology. , 2003, Analytical chemistry.

[38]  P. Kovanen,et al.  Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.

[39]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[40]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[41]  A. Burlingame,et al.  Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins. , 2003, Journal of lipid research.

[42]  E. Arias,et al.  Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[43]  A. Tall,et al.  Regulation and mechanisms of macrophage cholesterol efflux. , 2002, The Journal of clinical investigation.

[44]  D. Mangelsdorf,et al.  Regulated Expression of the Apolipoprotein E/C-I/C-IV/C-II Gene Cluster in Murine and Human Macrophages , 2002, The Journal of Biological Chemistry.

[45]  P. Ridker,et al.  Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ , 2001 .

[46]  A. Chait,et al.  Biglycan, a Vascular Proteoglycan, Binds Differently to HDL2 and HDL3: Role of ApoE , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[47]  J. Blake,et al.  Creating the Gene Ontology Resource : Design and Implementation The Gene Ontology Consortium 2 , 2001 .

[48]  P. Stetson,et al.  Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation* , 2000, The Journal of Biological Chemistry.

[49]  N. Baroukh,et al.  Expression of Human Apolipoprotein A-I/C-III/A-IV Gene Cluster in Mice Induces Hyperlipidemia but Reduces Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[50]  S. Wright,et al.  Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP). , 2000, Blood.

[51]  B. Dahlbäck,et al.  A Novel Human Apolipoprotein (apoM)* , 1999, The Journal of Biological Chemistry.

[52]  J. Yates,et al.  Direct analysis of protein complexes using mass spectrometry , 1999, Nature Biotechnology.

[53]  E. Braunwald Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[54]  P. Duchateau,et al.  Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas , 1997, The Journal of Biological Chemistry.

[55]  R. Havel,et al.  Identification, Characterization, Cloning, and Expression of Apolipoprotein C-IV, a Novel Sialoglycoprotein of Rabbit Plasma Lipoproteins (*) , 1996, The Journal of Biological Chemistry.

[56]  J. Kane,et al.  Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. , 1994, Biochemistry.

[57]  H. Wilson,et al.  Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[58]  Jing Zhao,et al.  Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. , 1993, The Journal of biological chemistry.

[59]  J P Kane,et al.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Mendez,et al.  Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. , 1991, The Journal of biological chemistry.

[61]  M J Davies,et al.  A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.

[62]  A. Tall,et al.  Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. , 1990, The Journal of clinical investigation.

[63]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[64]  P. Wilson,et al.  High density lipoprotein cholesterol and mortality. The Framingham Heart Study. , 1988, Arteriosclerosis.

[65]  M. Cheung,et al.  Differential effect of ultracentrifugation on apolipoprotein A-I-containing lipoprotein subpopulations. , 1988, Journal of lipid research.

[66]  G. Anantharamaiah,et al.  Characterization of high density lipoprotein subspecies: structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatography. , 1987, Journal of lipid research.

[67]  J. Kane,et al.  Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Strunk,et al.  Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. , 1983, Immunology.